Brent Fraser is CADTH Vice-President, Pharmaceutical Reviews, with responsibility for the CADTH drug products and services including the CADTH Common Drug Review (CDR), the pan-Canadian Oncology Drug Review (pCODR).
Brent is dedicated to building a team-based, client-oriented culture that values leadership, excellence, collaboration, and responsiveness. He champions customer service, business discipline, and ongoing process improvement, and he challenges his team to deliver high-quality, relevant, and timely assessments of drugs using the best available science, tools, and methodologies.
Brent is known for his strength as a thoughtful, listening, and collaborative leader who is adept at translating evidence into recommendations and actions. He combines a pharmacist’s appreciation for the clinical and human implications of his work with almost two decades of strategic experience within the largest public drug plan in the country.
Prior to joining CADTH in 2015, Brent held a variety of positions within the Ontario Public Drug Programs, where he was a key leader in the development of a pan-Canadian approach to pharmaceutical negotiations. Prior to that he was a pharmacist at the Hospital for Sick Children in Toronto.
Agenda: Day 1 Oct 6, 2020
Agenda: Day 2 Oct 7, 2020
Presentation: QUEBEC UPDATE
Prepare for the Potential National Implications of Quebec’s New PLA System
In early summer 2021, INESSS announced a change in their guidelines for listing applications. Arm your team with the knowledge to prepare for potential changes, and investigate how these revisions could affect the rest of the country. Develop a blueprint to:
- Review learnings from the Quebec market to-date.
- Understand why INESSS/Quebec instituted these particular changes.
- Gain valuable insight into specifics you may have missed.
Position your company to succeed in an uncertain environment with a solid public PLA strategy.